Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.06 and traded as low as $0.06. Nascent Biotech shares last traded at $0.06, with a volume of 41,000 shares changing hands.
Nascent Biotech Stock Performance
The business’s 50-day simple moving average is $0.06 and its two-hundred day simple moving average is $0.06.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Featured Articles
- Five stocks we like better than Nascent Biotech
- Most Volatile Stocks, What Investors Need to Know
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- What Are Growth Stocks and Investing in Them
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What to Know About Investing in Penny Stocks
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
